Corium International, Inc. (CORI) Sets New 1-Year High at $10.40
Corium International, Inc. (NASDAQ:CORI) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $10.40 and last traded at $10.37, with a volume of 144,014 shares. The stock had previously closed at $10.16.
A number of equities research analysts have recently weighed in on CORI shares. Needham & Company LLC reiterated a “buy” rating and issued a $13.00 price target on shares of Corium International in a report on Sunday. Jefferies Group LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Corium International in a report on Wednesday, July 19th. WBB Securities upgraded Corium International to a “buy” rating and set a $13.00 price target for the company in a report on Friday, July 7th. BidaskClub downgraded Corium International from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Zacks Investment Research downgraded Corium International from a “buy” rating to a “hold” rating in a report on Tuesday, July 11th. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $12.21.
The company’s market capitalization is $382.08 million. The company has a 50-day moving average price of $8.44 and a 200 day moving average price of $6.67.
Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.13). Corium International had a negative net margin of 145.60% and a negative return on equity of 673.17%. The business had revenue of $8.11 million for the quarter, compared to analyst estimates of $8.71 million. Analysts anticipate that Corium International, Inc. will post ($1.69) earnings per share for the current year.
In other Corium International news, major shareholder Life Sciences Maste Perceptive purchased 301,004 shares of the company’s stock in a transaction that occurred on Friday, June 30th. The stock was purchased at an average cost of $7.71 per share, with a total value of $2,320,740.84. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Timothy D. Sweemer sold 15,488 shares of the firm’s stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $7.82, for a total value of $121,116.16. The disclosure for this sale can be found here. Insiders have sold a total of 91,953 shares of company stock valued at $705,258 over the last ninety days. Insiders own 46.50% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in CORI. Perceptive Advisors LLC bought a new position in Corium International in the 1st quarter valued at $11,096,000. AWM Investment Company Inc. boosted its position in Corium International by 1,125.9% in the 1st quarter. AWM Investment Company Inc. now owns 2,451,700 shares of the biopharmaceutical company’s stock valued at $10,248,000 after buying an additional 2,251,700 shares during the last quarter. Broadfin Capital LLC boosted its position in Corium International by 45.2% in the 1st quarter. Broadfin Capital LLC now owns 2,787,121 shares of the biopharmaceutical company’s stock valued at $11,650,000 after buying an additional 867,400 shares during the last quarter. Stonepine Capital Management LLC bought a new position in Corium International in the 2nd quarter valued at $3,085,000. Finally, Royce & Associates LP boosted its position in Corium International by 208.4% in the 1st quarter. Royce & Associates LP now owns 548,464 shares of the biopharmaceutical company’s stock valued at $2,293,000 after buying an additional 370,600 shares during the last quarter. Hedge funds and other institutional investors own 90.14% of the company’s stock.
About Corium International
Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.
Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.